Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) will present its fourth quarter and full year 2025 results on Thursday, February 26, 2026 at 4:30 p.m. ET. The company said the presentation will include a review of business performance for the period ended December 31, 2025, with a live webcast and later replay available on its investor relations website.
Investors can submit questions in advance via X (hashtag #GinkgoResults) or by emailing investors@ginkgobioworks.com.
Positive
- None.
Negative
- None.
News Market Reaction – DNA
On the day this news was published, DNA gained 8.27%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.3% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $45M to the company's valuation, bringing the market cap to $589M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows only XNCR moving up, with no broad biotech peer participation, suggesting this is not part of a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | AI lab benchmark | Positive | +0.6% | AI-driven autonomous lab cut protein synthesis costs versus prior benchmarks. |
| Jan 13 | Conference appearance | Neutral | +0.6% | Planned presentation at the J.P. Morgan Healthcare Conference for investor outreach. |
| Dec 22 | Oncology partnership | Positive | +8.5% | ARPA-H–backed collaboration on innovative pill-based cancer screening tools. |
| Dec 17 | Agriculture collaboration | Positive | -0.2% | Collaboration with Agricen to optimize fermentation for soil amendment product. |
| Dec 09 | Drug safety project | Positive | +1.7% | Deep Origin-led ARPA-H project using Ginkgo’s platform for drug safety data. |
Recent news on partnerships and technology advances often saw modest positive reactions, with one stronger move on the cancer screening partnership and one mild divergence.
Over the last several months, Ginkgo reported AI-driven lab efficiency gains, conference participation, and multiple partnerships, including ARPA-H–linked oncology screening and drug safety initiatives. Price reactions were generally modestly positive, with the cancer screening partnership on Dec 22, 2025 showing a stronger 8.52% move. One collaboration update on Dec 17, 2025 saw a slight negative reaction, indicating occasional divergence. Today’s earnings date announcement fits a pattern of informational updates ahead of more material results releases.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration filed on 2025-08-07, with at least one related prospectus supplement (424B5) filed on 2025-09-04, indicating the ability to raise capital through registered offerings.
Market Pulse Summary
The stock moved +8.3% in the session following this news. A strong positive reaction aligns with expectations that earnings dates can concentrate attention on upcoming fundamentals. Past news, such as the ARPA-H oncology partnership with a 8.52% move, showed the stock responding to clear catalysts. However, existing capital-raising capacity under the Form S-3 and prior at-the-market authorization could remain an overhang if used more extensively, so investors historically watched subsequent filings closely.
AI-generated analysis. Not financial advice.
Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026
The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.
To ask a question ahead of the presentation, please submit them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
MEDIA CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-date-of-fourth-quarter-and-full-year-2025-results-presentation-302691775.html
SOURCE Ginkgo Bioworks
FAQ
When will Ginkgo Bioworks (DNA) present its Q4 and full year 2025 results?
How can investors watch the Ginkgo Bioworks (DNA) February 26, 2026 webcast?
How can I submit questions ahead of the Ginkgo Bioworks (DNA) results presentation?
What period will Ginkgo Bioworks (DNA) review during the February 26, 2026 presentation?
Will there be a replay of the Ginkgo Bioworks (DNA) February 26, 2026 presentation?
What time zone is used for the Ginkgo Bioworks (DNA) February 26, 2026 presentation start time?
